OBJECTIVE: Evaluate whether four different brands/types of heparin coated syringes can represent a source of variability in blood gas analysis (BGA). DESIGN AND METHODS: Blood was collected from one hundred volunteers into different syringes: Syringe I (lithium heparin and calcium balanced); Syringe II: in-house prepared (sodium heparin); Syringe III: (spray-dried calcium-balanced lithium heparin); Syringe IV (lyophilized electrolyte-balanced lithium heparin). RESULTS: Significant differences were as follows: a) Syringe I vs II: pO(2), sO(2), pCO(2)(t), cHCO(3)(-), ctCO(2), base excess (BE), total hemoglobin (tHb), sodium (Na(+)), potassium (K(+)), calcium (Ca(2+)), glucose (Glu), lactate (Lac), O(2) Hb and p 50; b) Syringe I vs III: pH, pO(2), cHCO(3)(-), ctCO(2), BE, Na(+), Glu, Lac and p 50; c) Syringe I vs IV: pH, pO(2), sO(2), pCO(2)(t), BE, Na(+), K(+), Ca(2+), Glu, Lac and O(2) Hb; d) Syringe II vs III: pH, pO(2), sO(2), pCO(2)(t), cHCO(3)(-), ctCO(2), ctO(2), tHb, Na(+), K(+), Ca(2+), Lac and p 50; e) Syringe II vs IV: pH, pO(2), sO(2), pCO(2)(t), cHCO(3)(-), ctCO(2), BE, tHb, Na(+), K(+), Ca(2+), Lac, O(2) Hb and p 50; f) Syringe III vs IV: pH, pO(2), sO(2), cHCO(3)(-), ctCO(2), ctO(2), BE, Na(+), K(+), Ca(2+), O(2) Hb and p 50. CONCLUSION: The different manufacturers of syringes can represent new source of variability on BGA.
OBJECTIVE: Evaluate whether four different brands/types of heparin coated syringes can represent a source of variability in blood gas analysis (BGA). DESIGN AND METHODS: Blood was collected from one hundred volunteers into different syringes: Syringe I (lithium heparin and calcium balanced); Syringe II: in-house prepared (sodium heparin); Syringe III: (spray-dried calcium-balanced lithium heparin); Syringe IV (lyophilized electrolyte-balanced lithium heparin). RESULTS: Significant differences were as follows: a) Syringe I vs II: pO(2), sO(2), pCO(2)(t), cHCO(3)(-), ctCO(2), base excess (BE), total hemoglobin (tHb), sodium (Na(+)), potassium (K(+)), calcium (Ca(2+)), glucose (Glu), lactate (Lac), O(2) Hb and p 50; b) Syringe I vs III: pH, pO(2), cHCO(3)(-), ctCO(2), BE, Na(+), Glu, Lac and p 50; c) Syringe I vs IV: pH, pO(2), sO(2), pCO(2)(t), BE, Na(+), K(+), Ca(2+), Glu, Lac and O(2) Hb; d) Syringe II vs III: pH, pO(2), sO(2), pCO(2)(t), cHCO(3)(-), ctCO(2), ctO(2), tHb, Na(+), K(+), Ca(2+), Lac and p 50; e) Syringe II vs IV: pH, pO(2), sO(2), pCO(2)(t), cHCO(3)(-), ctCO(2), BE, tHb, Na(+), K(+), Ca(2+), Lac, O(2) Hb and p 50; f) Syringe III vs IV: pH, pO(2), sO(2), cHCO(3)(-), ctCO(2), ctO(2), BE, Na(+), K(+), Ca(2+), O(2) Hb and p 50. CONCLUSION: The different manufacturers of syringes can represent new source of variability on BGA.
Authors: Gabriel Lima-Oliveira; Giuseppe Lippi; Gian Luca Salvagno; Marise Danielle Raulino Campelo; Katharyne Soares Adala Tajra; Flavio dos Santos Gomes; Carlos David Valentim; Sylvio José Colonna Romano; Geraldo Picheth; Gian Cesare Guidi Journal: Blood Transfus Date: 2013-07-18 Impact factor: 3.443
Authors: Gabriel Lima-Oliveira; Giuseppe Lippi; Gian Luca Salvagno; Martina Montagnana; Geraldo Picheth; Gian Cesare Guidi Journal: Indian J Clin Biochem Date: 2013-04-03
Authors: Gabriel Lima-Oliveira; Giuseppe Lippi; Gian Luca Salvagno; Martina Montagnana; Giovanni Poli; Giovanni Pietro Solero; Geraldo Picheth; Gian Cesare Guidi Journal: ISRN Hematol Date: 2012-07-24
Authors: Gabriel Lima-Oliveira; Giuseppe Lippi; Gian Luca Salvagno; Martina Montagnana; Geraldo Picheth; Gian Cesare Guidi Journal: Biochem Med (Zagreb) Date: 2012 Impact factor: 2.313
Authors: Gabriel Lima-Oliveira; Giuseppe Lippi; Gian Luca Salvagno; Martina Montagnana; Geraldo Picheth; Gian Cesare Guidi Journal: Biochem Med (Zagreb) Date: 2013 Impact factor: 2.313
Authors: Gabriel Lima-Oliveira; Giuseppe Lippi; Gian Luca Salvagno; Martina Montagnana; Geraldo Picheth; Gian Cesare Guidi Journal: Biochem Med (Zagreb) Date: 2012 Impact factor: 2.313
Authors: Gabriel Lima-Oliveira; Giuseppe Lippi; Gian Luca Salvagno; Martina Montagnana; Geraldo Picheth; Gian Cesare Guidi Journal: Biochem Med (Zagreb) Date: 2013 Impact factor: 2.313